Open-Label, Dose Confirmation Study of Interstitial 131I-chTNT-1/B MAb (Cotara) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse.
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2016
At a glance
- Drugs Iodine I 131 derlotuximab biotin (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 11 Oct 2011 Status changed from active, no longer recruiting to completed, according to a SIRO Clinpharm media release.
- 07 Jun 2011 Interim results were presented at the 47th Annual Meeting of the American Society of Oncology (ASCO-2011).
- 19 May 2011 Interim results have been reported in a Peregrine Pharmaceuticals media release; additional results will be reported at ASCO-2011.